Last reviewed · How we verify
Oxaliplatin, calcium folinate, 5-fluorouracil
Oxaliplatin, calcium folinate, 5-fluorouracil is a Platinum-based chemotherapy combination (FOLFOX regimen) Small molecule drug developed by Karolinska University Hospital. It is currently in Phase 3 development for Metastatic colorectal cancer, Adjuvant treatment of stage III colon cancer, Advanced gastric cancer. Also known as: Platinum-Fluoropyrimidine Regimens (alternative 2b).
This combination chemotherapy regimen kills cancer cells by damaging DNA and inhibiting nucleotide synthesis, with oxaliplatin forming platinum-DNA adducts, 5-fluorouracil inhibiting thymidylate synthase, and calcium folinate enhancing 5-FU efficacy.
This combination chemotherapy regimen kills cancer cells by damaging DNA and inhibiting nucleotide synthesis, with oxaliplatin forming platinum-DNA adducts, 5-fluorouracil inhibiting thymidylate synthase, and calcium folinate enhancing 5-FU efficacy. Used for Metastatic colorectal cancer, Adjuvant treatment of stage III colon cancer, Advanced gastric cancer.
At a glance
| Generic name | Oxaliplatin, calcium folinate, 5-fluorouracil |
|---|---|
| Also known as | Platinum-Fluoropyrimidine Regimens (alternative 2b) |
| Sponsor | Karolinska University Hospital |
| Drug class | Platinum-based chemotherapy combination (FOLFOX regimen) |
| Target | DNA (oxaliplatin); thymidylate synthase (5-fluorouracil) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Oxaliplatin is a third-generation platinum compound that forms covalent DNA adducts, preventing DNA replication and transcription. 5-Fluorouracil is a pyrimidine antimetabolite that inhibits thymidylate synthase and incorporates into RNA, disrupting nucleotide synthesis. Calcium folinate (leucovorin) is a reduced folate that stabilizes the 5-FU–thymidylate synthase complex, increasing 5-FU cytotoxicity. Together, these agents provide synergistic anti-tumor activity.
Approved indications
- Metastatic colorectal cancer
- Adjuvant treatment of stage III colon cancer
- Advanced gastric cancer
- Pancreatic cancer
Common side effects
- Peripheral neuropathy
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Diarrhea
- Mucositis
- Fatigue
- Hand-foot syndrome
Key clinical trials
- Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (PHASE3)
- Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) (PHASE2)
- Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (PHASE1)
- Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body (PHASE3)
- A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) (PHASE3)
- A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (PHASE3)
- Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) (PHASE1, PHASE2)
- A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxaliplatin, calcium folinate, 5-fluorouracil CI brief — competitive landscape report
- Oxaliplatin, calcium folinate, 5-fluorouracil updates RSS · CI watch RSS
- Karolinska University Hospital portfolio CI
Frequently asked questions about Oxaliplatin, calcium folinate, 5-fluorouracil
What is Oxaliplatin, calcium folinate, 5-fluorouracil?
How does Oxaliplatin, calcium folinate, 5-fluorouracil work?
What is Oxaliplatin, calcium folinate, 5-fluorouracil used for?
Who makes Oxaliplatin, calcium folinate, 5-fluorouracil?
Is Oxaliplatin, calcium folinate, 5-fluorouracil also known as anything else?
What drug class is Oxaliplatin, calcium folinate, 5-fluorouracil in?
What development phase is Oxaliplatin, calcium folinate, 5-fluorouracil in?
What are the side effects of Oxaliplatin, calcium folinate, 5-fluorouracil?
What does Oxaliplatin, calcium folinate, 5-fluorouracil target?
Related
- Drug class: All Platinum-based chemotherapy combination (FOLFOX regimen) drugs
- Target: All drugs targeting DNA (oxaliplatin); thymidylate synthase (5-fluorouracil)
- Manufacturer: Karolinska University Hospital — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic colorectal cancer
- Indication: Drugs for Adjuvant treatment of stage III colon cancer
- Indication: Drugs for Advanced gastric cancer
- Also known as: Platinum-Fluoropyrimidine Regimens (alternative 2b)
- Compare: Oxaliplatin, calcium folinate, 5-fluorouracil vs similar drugs
- Pricing: Oxaliplatin, calcium folinate, 5-fluorouracil cost, discount & access